| 000 | 01865 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250517080244.0 | ||
| 264 | 0 | _c20160620 | |
| 008 | 201606s 0 0 eng d | ||
| 022 | _a2049-4408 | ||
| 024 | 7 |
_a10.1302/0301-620X.98B2.36161 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFarrier, A J | |
| 245 | 0 | 0 |
_aNew anti-resorptives and antibody mediated anti-resorptive therapy. _h[electronic resource] |
| 260 |
_bThe bone & joint journal _cFeb 2016 |
||
| 300 |
_a160-5 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAdaptor Proteins, Signal Transducing |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xpharmacology |
| 650 | 0 | 4 |
_aBisphosphonate-Associated Osteonecrosis of the Jaw _xetiology |
| 650 | 0 | 4 |
_aBone Density Conservation Agents _xpharmacology |
| 650 | 0 | 4 |
_aBone Morphogenetic Proteins _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aBone Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aBone Resorption _xdrug therapy |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 |
_aDenosumab _xpharmacology |
| 650 | 0 | 4 |
_aDiphosphonates _xtherapeutic use |
| 650 | 0 | 4 | _aDrug Approval |
| 650 | 0 | 4 |
_aFemoral Fractures _xchemically induced |
| 650 | 0 | 4 | _aGenetic Markers |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypocalcemia _xchemically induced |
| 650 | 0 | 4 |
_aOsteoporosis _xdrug therapy |
| 650 | 0 | 4 |
_aOsteoporotic Fractures _xdrug therapy |
| 650 | 0 | 4 | _aPractice Guidelines as Topic |
| 650 | 0 | 4 | _aQuality-Adjusted Life Years |
| 650 | 0 | 4 |
_aRANK Ligand _xantagonists & inhibitors |
| 700 | 1 | _aSanchez Franco, L C | |
| 700 | 1 | _aShoaib, A | |
| 700 | 1 | _aGulati, V | |
| 700 | 1 | _aJohnson, N | |
| 700 | 1 | _aUzoigwe, C E | |
| 700 | 1 | _aChoudhury, M Z | |
| 773 | 0 |
_tThe bone & joint journal _gvol. 98-B _gno. 2 _gp. 160-5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1302/0301-620X.98B2.36161 _zAvailable from publisher's website |
| 999 |
_c25707542 _d25707542 |
||